Time for a change in hard-to-heal wounds: Xelma is a novel treatment for hard-to-heal wounds, e.g. venous leg ulcers, diabetic foot ulcers and pressure ulcers. Xelma provides a temporary extracellular matrix protein for cell attachment. This biological treatment approach is novel because it is designed to restore the balance by replacing crucial components of the defective extracellular matrix. In clinical investigations Xelma has shown promising benefits in hard-to-heal wounds.
Initiates wound healing in hard-to-heal wounds
Functions as a temporary matrix for cell attachment
Areas of use
Xelma is indicated for hard to heal wounds e.g. venous leg ulcers, diabetic foot ulcers and pressure ulcers.
Xelma is intended for topical application and should be covered by a secondary dressing such as Mepitel®, Mepilex® or Mepilex® Border and applied to the wound surface once weekly. If no improvement is observed within 6 weeks the treatment is to be reassessed.
How Xelma works
When applied to the wound bed Xelma provides a temporary extracellular matrix protein for cell attachment. This creates favourable conditions for wound healing by restoring vital cell functions including proliferation, migration, and production of growth factors and essential extracellular matrix components. Restoration of the cellular and biochemical balance is facilitated in the hard-to-heal wound, which will promote wound healing.
The information on the page you are about to enter is intended for healthcare professionals
only. To enter our product section you need tick the box below and click "yes".
By clicking the tick box below you confirm that you are a health care professional.
If you are not a Healthcare professional please visit our patient
website for product information. Thank you!
Take me back to startpage
ATTENTION: Products shown may not be available in all countries. Indications for
use and product claims may vary from country to country. For market specific product
information, see the appropriate location section of this website